socs1沉默的DC疫苗抗喉癌效应的研究  

Anti-laryngocarcinoma Immunity of DC Vaccine which Silenced socs1 by siRNA

作　　者：远洋[1] 王雪峰[1] 江祺川[1] 张扬[2] 李兵[3] 

机构地区：[1]辽宁医学院耳鼻喉科,辽宁锦州121001 [2]北京大学医学部外科 [3]辽宁医学院附属第一医院眼科

出　　处：《肿瘤防治研究》2011年第12期1356-1359,共4页Cancer Research on Prevention and Treatment

基　　金：辽宁省自然科学基金资助项目(20082180)

摘　　要：目的研究socs1沉默的DC特异性抗肿瘤作用机制,并探讨RNAi技术在喉癌基因治疗中的应用前景,为DC的临床治疗提供新思路。方法以细胞因子GM-CSF、IL-4和TNF-α体外诱导扩增外周血单核细胞来源的DC,构建RNAi载体转染DC;Western blot检测SOCS1的表达情况;流式细胞术检测DC表面分子的表达;MTT法评估DC诱导细胞毒性T细胞的杀伤活性。结果 DC体外诱导培养成功;干扰序列5可显著下调SOCS1表达水平;socs1沉默联合喉癌Hep-2抗原致敏的DC可显著上调表面分子标志CD83、CD86和HLA-DR的表达;该组DC能高效诱导CTL的特异性杀伤作用,效靶比为50∶1时其杀伤活性显著高于对照组。结论 socs1沉默并负载喉癌Hep-2抗原的DC可以产生高效而特异性的抗喉癌免疫应答。Objective To investigate the specific antitumor mechanism of socs1 silent DC and discuss the prospect of RNAi in the gene therapy for laryngocarcinoma in order to provide novel ideas of DC＇s clinical applications.Methods Dendritic cells derived from peripheral blood monocytes were cultured in vitro in the presence of GM-CSF,IL-4 and TNF-α.Construct the RNAi vector and transfect it into DC.The expression of SOCS1 was analyzed by Western blot.The alterations of surface markers on mature DC,including CD83,CD86 and HLA-DR,were detected by flow cytometry.The specific killing activity of CTL induced by DC was evaluated by MTT assay.Results Dendritic cells were obtained successfully.The expression of SOCS1 decreased significantly under the influence of the 5th interference sequence.socs1 silent dendritic cells which were loaded with Hep-2 antigen had high expressions of CD83,CD86 and HLA-DR.It could also enhance the specific killing effect of CTL.The killing activity was significantly higher than control group when the effect cells and target cells were mixed up at the ratio of 50：1（P0.01）.Conclusion socs1 silent dendritic cells which were loaded with Hep-2 antigen could induce effective and specific anti-laryngocarcinoma immune responses.

关 键 词：细胞因子信号转导抑制因子1 RNA干扰 树突状细胞 喉癌 

分 类 号：R739.65[医药卫生—肿瘤] R730.51[医药卫生—临床医学]